Given its role in oncogenesis, HMGA1 is considered a promising therapeutic target. Strategies to inhibit HMGA1 function include the use of small molecules that disrupt its DNA-binding ability or RNA interference to reduce its expression. Blocking HMGA1 activity could potentially impede cancer cell growth and improve the efficacy of existing treatments.
